Market Overview:
The global immune globulin intravenous (IVIg) market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of immunodeficiency, autoimmune diseases, and acute infections. Additionally, the increasing demand for IVIg products from emerging markets is also contributing to the growth of the market. However, factors such as high cost and limited reimbursement are restraining the growth of this market. The IVIg liquid segment is expected to dominate the global immune globulin intravenous (IVIg) market during the forecast period owing to its high usage rates in various applications such as immunodeficiency, autoimmune diseases, and acute infections.
Product Definition:
Immune globulin intravenous (IGIV) is a medication made from human plasma that contains antibodies to help protect against infection. IGIV is used to treat severe or life-threatening infections, such as sepsis, meningitis, and pneumonia. It is also used to prevent infections in people who are at high risk, such as cancer patients and those receiving organ transplants.
IVIg Liquid:
IVIg (Immunoglobulin G) is a type of intravenous immunoglobulin used to treat immune deficiencies and certain types of cancers. IVIG treatments are usually done in hospital settings by infusion nurses or physicians. The treatment can take place at any time during the course of cancer, but most often it takes place when the patient is undergoing chemotherapy for cancer.
IVIg Powder:
IVIg powder is a ready-to-use solution of human immunoglobulin made in the laboratory. It is used to treat immune deficiencies and certain types of cancer. IVIg powder can replace antibodies in patients with an antibody deficiency or allergy to the vaccine itself.
Application Insights:
The global immune globulin intravenous (IV) market is categorized based on application into immunodeficiency diseases, autoimmune disease, and acute infection. The immunodeficiency diseases segment dominated the global market in 2017 owing to the increasing prevalence of HIV and other infectious diseases that result in reduced immunity.
The autoimmune disease segment is expected to witness a lucrative CAGR during the forecast period due to an increase in patients suffering from chronic conditions such as rheumatoid arthritis, lupus erythematosus, scleroderma, etc. IVIG administration has been found beneficial not only for treating but also preventing these disorders by boosting patient¢â‚¬â„¢s immunity levels.
Increasing awareness about IVIG therapy among patients diagnosed with an immune deficiency or having a high risk of developing one coupled with rising government initiatives are some of the factors responsible for driving this segment over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, high healthcare expenditure, and rising incidence of infectious diseases are some factors attributing to its largest share. In addition, increasing demand for products that can be used for both acute and chronic immune-related disorders is expected to drive the market growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare expenditure by governments along with growing awareness about IVIg treatment among patients & physicians especially in developing countries such as India & China. Moreover, increasing prevalence of immunodeficiency conditions due to aging coupled with urbanization has led Asia Pacific into a dominating position amongst all regions globally within seven years from 2018 which will be further consolidated by 2030 time frame.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global autoimmune disease market is expected to grow at a CAGR of 6.5% from 2016 to 2024, reaching a value of USD 121.9 billion by 2024. This is primarily owing to the increasing incidence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and systemic lupus erythematosus (SLE) across the globe.
- Rising awareness about immunoglobulin therapies: There is an increasing awareness among patients and healthcare professionals about the benefits of immunoglobulin therapies for various indications such as primary immune deficiencies, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). This is likely to drive the growth of the immune globulin intravenous market in future.
- Technological advancements in immunoglobulin production: The technological advancements in recombinant DNA technology have led to increased production capacity and improved quality control measures for various types of immunoglobulins including IgG, IgA, IgM, and IgE antibodies. This is likely to boost the demand for immune globulin intravenous products in future years..
- 6 billion by 2050.,This growing geriatric population base will create a large pool susceptibleto age-related
Scope Of The Report
Report Attributes
Report Details
Report Title
Immune Globulin Intravenous Market Research Report
By Type
IVIg Liquid, IVIg Powder
By Application
Immunodeficiency, Autoimmune Disease, Acute Infection
By Companies
Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Immune Globulin Intravenous Market Report Segments:
The global Immune Globulin Intravenous market is segmented on the basis of:
Types
IVIg Liquid, IVIg Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunodeficiency, Autoimmune Disease, Acute Infection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Grifols
- CSL
- Octapharma
- Biotest
- Kedrion
- Hualan Bio
- CNBG
- Shanghai RAAS
- CBPO
- LFB Group
- BPL
- Sichuan Yuanda Shuyang
Highlights of The Immune Globulin Intravenous Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IVIg Liquid
- IVIg Powder
- By Application:
- Immunodeficiency
- Autoimmune Disease
- Acute Infection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immune Globulin Intravenous Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immune globulin intravenous (IGIV) is a type of medication used to help the body fight infections. IGIV is given by injection into a vein.
Some of the key players operating in the immune globulin intravenous market are Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang.
The immune globulin intravenous market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immune Globulin Intravenous Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immune Globulin Intravenous Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immune Globulin Intravenous Market - Supply Chain
4.5. Global Immune Globulin Intravenous Market Forecast
4.5.1. Immune Globulin Intravenous Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immune Globulin Intravenous Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immune Globulin Intravenous Market Absolute $ Opportunity
5. Global Immune Globulin Intravenous Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immune Globulin Intravenous Market Size and Volume Forecast by Type
5.3.1. IVIg Liquid
5.3.2. IVIg Powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immune Globulin Intravenous Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immune Globulin Intravenous Market Size and Volume Forecast by Application
6.3.1. Immunodeficiency
6.3.2. Autoimmune Disease
6.3.3. Acute Infection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immune Globulin Intravenous Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immune Globulin Intravenous Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immune Globulin Intravenous Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immune Globulin Intravenous Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immune Globulin Intravenous Demand Share Forecast, 2019-2026
9. North America Immune Globulin Intravenous Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immune Globulin Intravenous Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immune Globulin Intravenous Market Size and Volume Forecast by Application
9.4.1. Immunodeficiency
9.4.2. Autoimmune Disease
9.4.3. Acute Infection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immune Globulin Intravenous Market Size and Volume Forecast by Type
9.7.1. IVIg Liquid
9.7.2. IVIg Powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immune Globulin Intravenous Demand Share Forecast, 2019-2026
10. Latin America Immune Globulin Intravenous Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immune Globulin Intravenous Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immune Globulin Intravenous Market Size and Volume Forecast by Application
10.4.1. Immunodeficiency
10.4.2. Autoimmune Disease
10.4.3. Acute Infection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immune Globulin Intravenous Market Size and Volume Forecast by Type
10.7.1. IVIg Liquid
10.7.2. IVIg Powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immune Globulin Intravenous Demand Share Forecast, 2019-2026
11. Europe Immune Globulin Intravenous Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immune Globulin Intravenous Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immune Globulin Intravenous Market Size and Volume Forecast by Application
11.4.1. Immunodeficiency
11.4.2. Autoimmune Disease
11.4.3. Acute Infection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immune Globulin Intravenous Market Size and Volume Forecast by Type
11.7.1. IVIg Liquid
11.7.2. IVIg Powder
11.8. Basis Pint Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immune Globulin Intravenous Demand Share, 2019-2026
12. Asia Pacific Immune Globulin Intravenous Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immune Globulin Intravenous Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immune Globulin Intravenous Market Size and Volume Forecast by Application
12.4.1. Immunodeficiency
12.4.2. Autoimmune Disease
12.4.3. Acute Infection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immune Globulin Intravenous Market Size and Volume Forecast by Type
12.7.1. IVIg Liquid
12.7.2. IVIg Powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immune Globulin Intravenous Demand Share, 2019-2026
13. Middle East & Africa Immune Globulin Intravenous Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immune Globulin Intravenous Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immune Globulin Intravenous Market Size and Volume Forecast by Application
13.4.1. Immunodeficiency
13.4.2. Autoimmune Disease
13.4.3. Acute Infection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immune Globulin Intravenous Market Size and Volume Forecast by Type
13.7.1. IVIg Liquid
13.7.2. IVIg Powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immune Globulin Intravenous Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Immune Globulin Intravenous Market: Market Share Analysis
14.2. Immune Globulin Intravenous Distributors and Customers
14.3. Immune Globulin Intravenous Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxter
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Grifols
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSL
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biotest
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Kedrion
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hualan Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CNBG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shanghai RAAS
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CBPO
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. LFB Group
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BPL
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sichuan Yuanda Shuyang
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
